Amy Paller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/568374/publications.pdf

Version: 2024-02-01

505 papers	32,134 citations	3933 88 h-index	6300 158 g-index
520 all docs	520 docs citations	520 times ranked	21934 citing authors

#	Article	IF	Citations
1	Activated STING in a Vascular and Pulmonary Syndrome. New England Journal of Medicine, 2014, 371, 507-518.	27.0	1,074
2	Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology, 2014, 71, 116-132.	1.2	970
3	Atopic dermatitis and the atopic march. Journal of Allergy and Clinical Immunology, 2003, 112, S118-S127.	2.9	946
4	Guidelines of care for the management ofÂatopicÂdermatitis. Journal of the American Academy of Dermatology, 2014, 70, 338-351.	1.2	889
5	Guidelines of care for the management of atopicÂdermatitis. Journal of the American Academy of Dermatology, 2014, 71, 327-349.	1.2	695
6	Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: Genetic and functional analyses. Cell, 1991, 66, 1301-1311.	28.9	657
7	Revised nomenclature and classification of inherited ichthyoses: Results of the First Ichthyosis Consensus Conference in SorÃ¨ze 2009. Journal of the American Academy of Dermatology, 2010, 63, 607-641.	1.2	610
8	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, 2019, 80, 1029-1072.	1.2	542
9	Binodal, wireless epidermal electronic systems with in-sensor analytics for neonatal intensive care. Science, 2019, 363, .	12.6	521
10	Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity. Pediatrics, 2009, 123, e808-e814.	2.1	441
11	Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. Journal of the American Academy of Dermatology, 2016, 75, 494-503.e6.	1.2	425
12	Etanercept Treatment for Children and Adolescents with Plaque Psoriasis. New England Journal of Medicine, 2008, 358, 241-251.	27.0	366
13	Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11975-11980.	7.1	361
14	Mutations in proteasome subunit Î² type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis and Rheumatism, 2012, 64, 895-907.	6.7	340
15	The genetic basis of epidermolytic hyperkeratosis: A disorder of differentiation-specific epidermal keratin genes. Cell, 1992, 70, 811-819.	28.9	335
16	The microbiome in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2019, 143, 26-35.	2.9	317
17	Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. Journal of Allergy and Clinical Immunology, 2016, 138, 1639-1651.	2.9	309
18	Genetic and Clinical Mosaicism in a Type of Epidermal Nevus. New England Journal of Medicine, 1994, 331, 1408-1415.	27.0	307

#	Article	IF	Citations
19	Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis. JAMA Dermatology, 2020, 156, 44.	4.1	297
20	Increasing Comorbidities Suggest that Atopic DermatitisÂIsÂaÂSystemic Disorder. Journal of Investigative Dermatology, 2017, 137, 18-25.	0.7	283
21	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology, 2019, 80, 1073-1113.	1.2	281
22	A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology, 2001, 44, S47-S57.	1.2	278
23	Baricitinib in patients with moderateâ€toâ€severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials. British Journal of Dermatology, 2020, 183, 242-255.	1.5	277
24	Patient perspectives on the management of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2006, 118, 226-232.	2.9	274
25	Skin-interfaced biosensors for advanced wireless physiological monitoring in neonatal and pediatric intensive-care units. Nature Medicine, 2020, 26, 418-429.	30.7	272
26	Incontinentia pigmenti: A review and update on the molecular basis of pathophysiology. Journal of the American Academy of Dermatology, 2002, 47, 169-190.	1.2	269
27	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet, The, 2021, 397, 2151-2168.	13.7	259
28	Sleep Disturbances in Adults with Eczema Are Associated with Impaired Overall Health: A US Population-Based Study. Journal of Investigative Dermatology, 2015, 135, 56-66.	0.7	258
29	Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology, 2014, 71, 1218-1233.	1.2	256
30	The atopic march and atopic multimorbidity: Many trajectories, many pathways. Journal of Allergy and Clinical Immunology, 2019, 143, 46-55.	2.9	246
31	Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis. JAMA Dermatology, 2020, 156, 411.	4.1	241
32	Pediatric morphea (localized scleroderma): Review of 136 patients. Journal of the American Academy of Dermatology, 2008, 59, 385-396.	1.2	232
33	Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. Journal of Allergy and Clinical Immunology, 2009, 124, 260-269.e7.	2.9	227
34	Multifunctional Skinâ€Like Electronics for Quantitative, Clinical Monitoring of Cutaneous Wound Healing. Advanced Healthcare Materials, 2014, 3, 1597-1607.	7.6	226
35	Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11Âyears old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology, 2020, 83, 1282-1293.	1.2	214
36	Treatment of cutaneous hemangiomas by the flashlamp-pumped pulsed dye laser: Prospective analysis. Journal of Pediatrics, 1992, 120, 555-560.	1.8	199

#	Article	IF	Citations
37	Loss-of-function mutations of an inhibitory upstream ORF in the human hairless transcript cause Marie Unna hereditary hypotrichosis. Nature Genetics, 2009, 41, 228-233.	21.4	190
38	Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. Journal of the American Academy of Dermatology, 2010, 62, 489-495.	1.2	189
39	siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5573-5578.	7.1	189
40	Ustekinumab in adolescent patients age 12 to 17Âyears with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. Journal of the American Academy of Dermatology, 2015, 73, 594-603.	1.2	187
41	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal of the American Academy of Dermatology, 2020, 82, 1445-1486.	1.2	184
42	Topical calcipotriene for morphea/linear scleroderma. Journal of the American Academy of Dermatology, 1998, 39, 211-215.	1.2	182
43	Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. Journal of Allergy and Clinical Immunology, 2018, 141, 2094-2106.	2.9	176
44	Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire CLA+ TH22/TC22 cell subsets. Journal of Allergy and Clinical Immunology, 2015, 136, 941-951.e3.	2.9	175
45	Mutations in Capillary Morphogenesis Gene-2 Result in the Allelic Disorders Juvenile Hyaline Fibromatosis and Infantile Systemic Hyalinosis. American Journal of Human Genetics, 2003, 73, 957-966.	6.2	174
46	A systematic review of the safety of topical therapies for atopic dermatitis. British Journal of Dermatology, 2007, 156, 203-221.	1.5	171
47	Therapeutic pipeline for atopic dermatitis: End of the drought?. Journal of Allergy and Clinical Immunology, 2017, 140, 633-643.	2.9	171
48	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of the American Academy of Dermatology, 2017, 77, 623-633.	1.2	170
49	Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. American Journal of Clinical Dermatology, 2018, 19, 821-838.	6.7	159
50	The epidemiology of molluscum contagiosum in children. Journal of the American Academy of Dermatology, 2006, 54, 47-54.	1.2	153
51	LUMBAR: Association between Cutaneous Infantile Hemangiomas of the Lower Body and Regional Congenital Anomalies. Journal of Pediatrics, 2010, 157, 795-801.e7.	1.8	153
52	The Roles of Growth Factors in Keratinocyte Migration. Advances in Wound Care, 2015, 4, 213-224.	5.1	149
53	Association of Pediatric Psoriasis Severity With Excess and Central Adiposity. JAMA Dermatology, 2013, 149, 166.	4.1	148
54	A systematic review of topical corticosteroid withdrawal (â€œsteroid addictionâ€) in patients with atopic dermatitis and other dermatoses. Journal of the American Academy of Dermatology, 2015, 72, 541-549.e2.	1.2	146

#	Article	IF	Citations
55	Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults. British Journal of Dermatology, 2016, 175, 920-929.	1.5	142
56	Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1519-1531.	3.8	141
57	Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology, 2005, 52, 810-822.	1.2	138
58	Langerhans Cell Histiocytosis Presenting in the Neonatal Period. JAMA Pediatrics, 2001, 155, 778.	3.0	136
59	An IL-17â€“dominant immune profile is shared across the major orphan forms of ichthyosis. Journal of Allergy and Clinical Immunology, 2017, 139, 152-165.	2.9	135
60	Joint AADâ€“NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal of the American Academy of Dermatology, 2021, 84, 432-470.	1.2	135
61	Tacrolimus ointment promotes repigmentation of vitiligo in children: A review of 57 cases. Journal of the American Academy of Dermatology, 2004, 51, 760-766.	1.2	134
62	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal of the American Academy of Dermatology, 2020, 82, 161-201.	1.2	129
63	JAK inhibitors in the treatment of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2021, 148, 927-940.	2.9	129
64	Persistent association of nailfold capillaroscopy changes and skin involvement over thirtyâ€six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis and Rheumatism, 2008, 58, 571-576.	6.7	128
65	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. British Journal of Dermatology, 2018, 178, 768-775.	1.5	127
66	Association of facial hemangiomas with Dandy-Walker and other posterior fossa malformations. Journal of Pediatrics, 1993, 122, 379-384.	1.8	125
67	Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. Journal of the American Academy of Dermatology, 2005, 53, S186-S194.	1.2	125
68	Pityriasis lichenoides in childhood: A retrospective review of 124 patients. Journal of the American Academy of Dermatology, 2007, 56, 205-210.	1.2	124
69	Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial. Pediatrics, 2015, 135, 597-606.	2.1	123
70	New treatments in atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2021, 126, 21-31.	1.0	120
71	Extracellular Matrix Protein 1 Gene (ECM1) Mutations in Lipoid Proteinosis and Genotype-Phenotype Correlation. Journal of Investigative Dermatology, 2003, 120, 345-350.	0.7	119
72	A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. Journal of the American Academy of Dermatology, 2019, 80, 89-98.e3.	1.2	118

#	Article	IF	Citations
73	Nocturnal eczema: Review of sleep and circadian rhythms in children with atopic dermatitis and future research directions. Journal of Allergy and Clinical Immunology, 2015, 136, 1170-1177.	2.9	117
74	Partial albinism with immunodeficiency: Griscelli syndrome: Report of a case and review of the literature. Journal of the American Academy of Dermatology, 1998, 38, 295-300.	1.2	116
75	Mutations in the Glycosylphosphatidylinositol Gene PIGL Cause CHIME Syndrome. American Journal of Human Genetics, 2012, 90, 685-688.	6.2	114
76	Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis. JAMA Dermatology, 2019, 155, 1358.	4.1	113
77	Aquagenic palmoplantar keratoderma. Journal of the American Academy of Dermatology, 2001, 44, 696-699.	1.2	111
78	AAD consensus statement on psoriasis therapies. Journal of the American Academy of Dermatology, 2003, 49, 897-899.	1.2	110
79	From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. Journal of the American Academy of Dermatology, 2008, 58, 94-105.	1.2	109
80	Bullous Systemic Lupus Erythematosus With Autoantibodies Recognizing Multiple Skin Basement Membrane Components, Bullous Pemphigoid Antigen 1, Laminin-5, Laminin-6, and Type VII Collagen. Archives of Dermatology, 1999, 135, 569-73.	1.4	108
81	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology, 2019, 81, 775-804.	1.2	105
82	The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. British Journal of Dermatology, 2020, 182, 1331-1342.	1.5	102
83	Study of the Atopic March: Development of Atopic Comorbidities. Pediatric Dermatology, 2016, 33, 388-398.	0.9	99
84	Topically Applied Imiquimod Inhibits Vascular Tumor Growth In Vivo. Journal of Investigative Dermatology, 2003, 121, 1205-1209.	0.7	97
85	Suppression of Epidermal Growth Factor Receptor Signaling by Protein Kinase C-Î± Activation Requires CD82, Caveolin-1, and Ganglioside. Cancer Research, 2007, 67, 9986-9995.	0.9	96
86	Long-term etanercept in pediatric patients with plaque psoriasis. Journal of the American Academy of Dermatology, 2010, 63, 762-768.	1.2	96
87	Pathogenesis-Based Therapy Reverses Cutaneous Abnormalities in an Inherited Disorder of Distal Cholesterol Metabolism. Journal of Investigative Dermatology, 2011, 131, 2242-2248.	0.7	95
88	Cimetidine therapy for multiple viral warts in children. Journal of the American Academy of Dermatology, 1993, 28, 794-796.	1.2	92
89	Clinical Manifestations of Pediatric Psoriasis: Results of a Multicenter Study in the United States. Pediatric Dermatology, 2013, 30, 424-428.	0.9	92
90	A novel KIT mutation results in piebaldism with progressive depigmentation. Journal of the American Academy of Dermatology, 2001, 44, 288-292.	1.2	89

#	Article	IF	Citations
91	Perceptions of Physicians and Pediatric Patients About Atopic Dermatitis, Its Impact, and Its Treatment. Clinical Pediatrics, 2002, 41, 323-332.	0.8	88
92	Tacrolimus Ointment is Effective for Psoriasis on the Face and Intertriginous Areas in Pediatric Patients. Pediatric Dermatology, 2007, 24, 76-80.	0.9	86
93	Central Obesity and High Blood Pressure in Pediatric Patients With Atopic Dermatitis. JAMA Dermatology, 2015, 151, 144.	4.1	86
94	Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. Journal of the American Academy of Dermatology, 2016, 74, 280-287.e3.	1.2	84
95	Pediatric Psoriasis Comorbidity Screening Guidelines. JAMA Dermatology, 2017, 153, 698.	4.1	84
96	Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. Journal of the American Academy of Dermatology, 2017, 76, 811-817.e4.	1.2	83
97	CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. Journal of the American Academy of Dermatology, 2018, 79, 487-494.	1.2	82
98	Phosphodiesterase 4 inhibitors. Journal of the American Academy of Dermatology, 2018, 78, S43-S52.	1.2	81
99	Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature. Journal of Allergy and Clinical Immunology, 2019, 143, 604-618.	2.9	80
100	The Misnomer â€œMacrocephalyâ€“Cutis Marmorata Telangiectatica Congenita Syndromeâ€• Archives of Dermatology, 2009, 145, 287-93.	1.4	79
101	Whole-Exome Sequencing Reveals Somatic Mutations in HRAS and KRAS , which Cause Nevus Sebaceus. Journal of Investigative Dermatology, 2013, 133, 827-830.	0.7	79
102	Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care Providers. Pediatrics, 2015, 136, 554-565.	2.1	78
103	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. Journal of the American Academy of Dermatology, 2020, 83, 839-846.	1.2	78
104	Epidermal growth factor receptor glycosylation is required for ganglioside GM3 binding and GM3-mediated suppresion of activation. Glycobiology, 2001, 11, 515-522.	2.5	77
105	Ganglioside GM3 Blocks the Activation of Epidermal Growth Factor Receptor Induced by Integrin at Specific Tyrosine Sites. Journal of Biological Chemistry, 2003, 278, 48770-48778.	3.4	77
106	Kawasaki disease. Journal of the American Academy of Dermatology, 2013, 69, 513.e1-513.e8.	1.2	77
107	Efficacy and safety of ixekizumab in a phase <scp>III</scp> , randomized, doubleâ€blind, placeboâ€controlled study in paediatric patients with moderateâ€toâ€severe plaque psoriasis () Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.4	77
108	Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. Journal of the American Academy of Dermatology, 2021, 84, 632-638.	1.2	77

#	Article	IF	Citations
109	Response of deep tufted angioma to interferon alfa. Journal of the American Academy of Dermatology, 1995, 33, 124-126.	1.2	76
110	The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. Journal of the American Academy of Dermatology, 2019, 81, 510-519.	1.2	76
111	Ultrapotent Topical Corticosteroid Treatment of Childhood Genital Lichen Sclerosus. Archives of Dermatology, 1999, 135, 525-8.	1.4	75
112	Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. JAMA Dermatology, 2017, 153, 1147.	4.1	75
113	MAS063DP is Effective Monotherapy for Mild to Moderate Atopic Dermatitis in Infants and Children: A Multicenter, Randomized, Vehicle-Controlled Study. Journal of Pediatrics, 2008, 152, 854-859.	1.8	74
114	Nasal Midline Masses in Infants and Children. Archives of Dermatology, 1991, 127, 362.	1.4	73
115	Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. Journal of the American Academy of Dermatology, 2017, 76, 281-285.	1.2	73
116	Cutaneous granulomatous lesions in patients with ataxia-telangiectasia. Journal of Pediatrics, 1991, 119, 917-922.	1.8	72
117	Three Times Weekly Tacrolimus Ointment Reduces Relapse in Stabilized Atopic Dermatitis: A New Paradigm for Use. Pediatrics, 2008, 122, e1210-e1218.	2.1	72
118	New Insights About Infant and Toddler Skin: Implications for Sun Protection. Pediatrics, 2011, 128, 92-102.	2.1	72
119	The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. Journal of Allergy and Clinical Immunology, 2021, 148, 148-163.	2.9	72
120	Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatric Allergy and Immunology, 2015, 26, 306-315.	2.6	71
121	Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy. Journal of the American Academy of Dermatology, 2020, 82, 123-131.	1.2	71
122	Squaric acid immunotherapy for warts in children. Journal of the American Academy of Dermatology, 2000, 42, 803-808.	1.2	70
123	Carbohydrate-Carbohydrate Binding of Ganglioside to Integrin Î±5Î²1Function. Journal of Biological Chemistry, 2001, 276, 8436-8444.	3.4	70
124	Ganglioside Induces Caveolin-1 Redistribution and Interaction with the Epidermal Growth Factor Receptor. Journal of Biological Chemistry, 2002, 277, 47028-47034.	3.4	70
125	Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. Journal of Allergy and Clinical Immunology, 2020, 145, 215-228.	2.9	70
126	Sleep disturbance in children with moderate/severe atopic dermatitis: A case-control study. Journal of the American Academy of Dermatology, 2018, 78, 336-341.	1.2	68

#	Article	IF	Citations
127	Mutations in KDSR Cause Recessive Progressive Symmetric Erythrokeratoderma. American Journal of Human Genetics, 2017, 100, 978-984.	6.2	67
128	Abnormal scar identification with spherical-nucleic-acid technology. Nature Biomedical Engineering, 2018, 2, 227-238.	22.5	67
129	Pediatric psoriasis: Evolving perspectives. Pediatric Dermatology, 2018, 35, 170-181.	0.9	66
130	Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. Journal of the American Academy of Dermatology, 2011, 64, 64-70.	1.2	65
131	No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. Journal of the American Academy of Dermatology, 2020, 83, 375-381.	1.2	64
132	Consequences of Seven Novel Mutations on the Expression and Structure of Keratinocyte Transglutaminase. Journal of Biological Chemistry, 1997, 272, 21018-21026.	3.4	63
133	Pachyonychia Congenita in Pediatric Patients. JAMA Dermatology, 2014, 150, 146.	4.1	63
134	Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. Journal of the American Academy of Dermatology, 2003, 48, 553-563.	1.2	62
135	Inhibition of Integrin-linked Kinase/Protein Kinase B/Akt Signaling. Journal of Biological Chemistry, 2001, 276, 44504-44511.	3.4	61
136	Asymptomatic Inflammatory Bowel Disease Presenting With Mucocutaneous Findings. Pediatrics, 2005, 116, e439-e444.	2.1	61
137	Methotrexate: New Uses for an Old Drug. Journal of Pediatrics, 2014, 164, 231-236.	1.8	61
138	Tape strips from earlyâ€onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 314-325.	5.7	61
139	Atopic Dermatitis: Epidemiology and Pathogenesis Update. Seminars in Cutaneous Medicine and Surgery, 2012, 31, S3-S5.	1.6	60
140	Incontinentia pigmenti in male patients. Journal of the American Academy of Dermatology, 2006, 55, 251-255.	1.2	59
141	Infantile acropustulosis revisited: history of scabies and response to topical corticosteroids.. Pediatric Dermatology, 1998, 15, 337-341.	0.9	58
142	The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab. Journal of the American Academy of Dermatology, 2018, 78, 498-505.e2.	1.2	58
143	Human and computational models of atopic dermatitis: AÂreview and perspectives by an expert panel of the International Eczema Council. Journal of Allergy and Clinical Immunology, 2019, 143, 36-45.	2.9	58
144	Understanding and Managing Atopic Dermatitis in Adult Patients. Seminars in Cutaneous Medicine and Surgery, 2012, 31, S18-S22.	1.6	57

#	Article	IF	Citations
145	Frequent somatic reversion of KRT1 mutations in ichthyosis with confetti. Journal of Clinical Investigation, 2015, 125, 1703-1707.	8.2	57
146	The relationship between family medical history and childhood vitiligo. Journal of the American Academy of Dermatology, 2006, 55, 238-244.	1.2	56
147	Second-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis. JAMA Dermatology, 2019, 155, 548.	4.1	56
148	Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. American Journal of Clinical Dermatology, 2020, 21, 119-131.	6.7	56
149	Prenatal Diagnosis for Recessive Dystrophic Epidermolysis Bullosa in 10 Families by Mutation and Haplotype Analysis in the Type VII Collagen Gene (COL7A1). Molecular Medicine, 1996, 2, 59-76.	4.4	55
150	Food Allergy in Infants With Atopic Dermatitis: Limitations of Food-Specific IgE Measurements. Pediatrics, 2015, 136, e1530-e1538.	2.1	55
151	Consensus Statement on the Safety Profile of Topical Calcineurin Inhibitors. Dermatology, 2005, 211, 77-78.	2.1	54
152	American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults. Journal of the American Academy of Dermatology, 2022, 86, 1335-1336.e18.	1.2	54
153	Ustekinumab for the treatment of moderateâ€toâ€severe plaque psoriasis in paediatric patients (â‰¥ 6 to <) Tj ETQq1 1 0.78431 <scp>CADMUS</scp> Jr study. British Journal of Dermatology, 2020, 183, 664-672.	1.5	53
154	A Mouse Monoclonal Antibody Against a Newly Discovered Basement Membrane Component, the Epidermolysis Bullosa Acquisita Antigen. Journal of Investigative Dermatology, 1985, 84, 215-217.	0.7	52
155	Pyoderma gangrenosum in pediatric acquired immunodeficiency syndrome. Journal of Pediatrics, 1990, 117, 63-66.	1.8	52
156	A phase 2, openâ€label study of singleâ€dose dupilumab in children aged 6Âmonths to <6Âyears with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 464-475.	2.4	52
157	Dilute Bleach Baths for Staphylococcus aureus Colonization in Atopic Dermatitis to Decrease Disease Severity. Archives of Dermatology, 2011, 147, 246.	1.4	51
158	Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. Journal of the American Academy of Dermatology, 2012, 67, 918-923.	1.2	51
159	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy â€“ international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1224-1231.	2.4	50
160	Two Cases of Primarily Palmoplantar Keratoderma Associated with Novel Mutations in Keratin 1. Journal of Investigative Dermatology, 2002, 119, 966-971.	0.7	49
161	Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti. Clinical and Experimental Immunology, 2002, 127, 470-478.	2.6	49
162	Wnt signaling in focal dermal hypoplasia. Nature Genetics, 2007, 39, 820-821.	21.4	49

#	Article	IF	Citations
163	Ganglioside GM3 Depletion Reverses Impaired Wound Healing in Diabetic Mice by Activating IGF-1 and Insulin Receptors. Journal of Investigative Dermatology, 2014, 134, 1446-1455.	0.7	49
164	Prevalence and Characterization of Pruritus in Epidermolysis Bullosa. Pediatric Dermatology, 2015, 32, 53-59.	0.9	49
165	Fibrous Hamartoma of Infancy. Archives of Dermatology, 1989, 125, 88.	1.4	48
166	Ganglioside GM3 Inhibits the Proliferation of Cultured Keratinocytes. Journal of Investigative Dermatology, 1993, 100, 841-845.	0.7	48
167	Dominant De Novo Mutations in GJA1 Cause Erythrokeratodermia Variabilis et Progressiva, without Features of Oculodentodigital Dysplasia. Journal of Investigative Dermatology, 2015, 135, 1540-1547.	0.7	48
168	Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations. Journal of the American Academy of Dermatology, 2018, 78, 579-590.e4.	1.2	48
169	Effects of a low-potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. Current Therapeutic Research, 1998, 59, 227-233.	1.2	47
170	Kawasaki disease. Journal of the American Academy of Dermatology, 2013, 69, 501.e1-501.e11.	1.2	47
171	Association Between Eczema and Stature in 9 US Population-Based Studies. JAMA Dermatology, 2015, 151, 401.	4.1	47
172	Cutaneous innervation in impaired diabetic wound healing. Translational Research, 2021, 236, 87-108.	5.0	47
173	Ganglioside Modulates Ligand Binding to the Epidermal Growth Factor Receptor. Journal of Investigative Dermatology, 2001, 116, 69-76.	0.7	46
174	Infantile systemic hyalinosis. Journal of the American Academy of Dermatology, 2004, 50, 61-64.	1.2	46
175	Excess Adiposity Preceding Pediatric Psoriasis. JAMA Dermatology, 2014, 150, 573.	4.1	46
176	Comprehensive pregnancy monitoring with a network of wireless, soft, and flexible sensors in high- and low-resource health settings. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	46
177	Pustular Miliaria Rubra: A Specific Cutaneous Finding of Type I Pseudohypoaldosteronism. Pediatric Dermatology, 2002, 19, 317-319.	0.9	45
178	Organ-Specific, Phylogenetic, and Ontogenetic Distribution of the Epidermolysis Bullosa Acquisita Antigen. Journal of Investigative Dermatology, 1986, 86, 376-379.	0.7	44
179	Filaggrin Gene Mutations in African Americans with Both Ichthyosis Vulgaris and Atopic Dermatitis. Pediatric Dermatology, 2014, 31, 489-492.	0.9	44
180	Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: Fertility risk of Food and Drug Administrationâ€“approved systemic therapies. Journal of the American Academy of Dermatology, 2016, 75, 528-534.	1.2	44

#	Article	IF	Citations
181	Erythema Dyschromicum Perstans in Prepubertal Children. Pediatric Dermatology, 2003, 20, 398-403.	0.9	43
182	Cutaneous dyspigmentation in patients with ganglioside GM3 synthase deficiency. American Journal of Medical Genetics, Part A, 2013, 161, 875-879.	1.2	43
183	The natural history of pediatric-onset discoid lupus erythematosus. Journal of the American Academy of Dermatology, 2015, 72, 628-633.	1.2	43
184	Alterations in B-cell subsets in pediatric patients with early atopic dermatitis. Journal of Allergy and Clinical Immunology, 2017, 140, 134-144.e9.	2.9	43
185	The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood. Journal of Investigative Dermatology, 2018, 138, 2157-2167.	0.7	43
186	Intermittent etanercept therapy in pediatric patients with psoriasis. Journal of the American Academy of Dermatology, 2010, 63, 769-774.	1.2	42
187	Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum. Journal of Allergy and Clinical Immunology, 2015, 136, 1591-1600.	2.9	42
188	New KIT mutations in patients with piebaldism. Journal of Dermatological Science, 2004, 35, 29-33.	1.9	41
189	Ganglioside GM3 Inhibits Matrix Metalloproteinase-9 Activation and Disrupts Its Association with Integrin. Journal of Biological Chemistry, 2003, 278, 25591-25599.	3.4	40
190	Acute Generalized Exanthematous Pustulosis in Children. Archives of Dermatology, 2004, 140, 1172-3.	1.4	40
191	Gangliosides Inhibit Urokinase-Type Plasminogen Activator (uPA)-Dependent Squamous Carcinoma Cell Migration by Preventing uPA Receptor/Î±5Î²1 Integrin/Epidermal Growth Factor Receptor Interactions. Journal of Investigative Dermatology, 2005, 124, 839-848.	0.7	40
192	Ectodermal dysplasiaâ€“skin fragility syndrome resulting from a new homozygous mutation, 888delC, in the desmosomal protein plakophilin 1. Journal of the American Academy of Dermatology, 2006, 55, 157-161.	1.2	40
193	Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients. Annals of Allergy, Asthma and Immunology, 2019, 122, 318-330.e3.	1.0	40
194	Adhesion and Migration, the Diverse Functions of the Laminin Î±3 Subunit. Dermatologic Clinics, 2010, 28, 79-87.	1.7	39
195	Histologic and Immunohistochemical Features of the Skin Lesions in CANDLE Syndrome. American Journal of Dermatopathology, 2015, 37, 517-522.	0.6	39
196	Pulmonary Hemorrhage: An Often Fatal Complication of Henoch-Schoenlein Purpura. Pediatric Dermatology, 1997, 14, 299-302.	0.9	38
197	A skin-conformable wireless sensor to objectively quantify symptoms of pruritus. Science Advances, 2021, 7, .	10.3	38
198	Disseminated Fusarium solani Infection With Cutaneous Nodules in a Bone Marrow Transplant Patient. International Journal of Dermatology, 1988, 27, 698-701.	1.0	37

#	Article	IF	Citations
199	Cost-effectiveness of Prophylactic Moisturization for Atopic Dermatitis. JAMA Pediatrics, 2017, 171, e163909.	6.2	37
200	Targeting the IL-17 Receptor Using Liposomal Spherical Nucleic Acids as Topical Therapy for Psoriasis. Journal of Investigative Dermatology, 2020, 140, 435-444.e4.	0.7	36
201	The Generalized Atrophic Benign Form of Junctional Epidermolysis Bullosa. Archives of Dermatology, 1986, 122, 704.	1.4	35
202	Pachyonychia Congenita Tarda. Archives of Dermatology, 1991, 127, 701.	1.4	35
203	Alteration in Keratinocyte Ganglioside Content in Basal Cell Carcinomas. Journal of Investigative Dermatology, 1992, 98, 226-232.	0.7	35
204	Hedgehog Hives. Archives of Dermatology, 1999, 135, 561-3.	1.4	35
205	In Vivo Gene Therapy with Interleukin-12 Inhibits Primary Vascular Tumor Growth and Induces Apoptosis in a Mouse Model1. Journal of Investigative Dermatology, 1999, 112, 775-781.	0.7	35
206	Fluocinolone acetonide 0.01% in peanut oil: Therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. Journal of the American Academy of Dermatology, 2003, 48, 569-577.	1.2	35
207	Diaper dermatitis prevalence and severity: Global perspective on the impact of caregiver behavior. Pediatric Dermatology, 2020, 37, 130-136.	0.9	34
208	Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. Pediatric Dermatology, 2021, 38, 164-180.	0.9	34
209	Mucocutaneous manifestations of the hyper-IgM immunodeficiency syndrome. Journal of the American Academy of Dermatology, 1998, 38, 191-196.	1.2	33
210	The acanthosis nigricans form of epidermal nevus. Journal of the American Academy of Dermatology, 2006, 55, 696-698.	1.2	33
211	Insights from a Desmoplakin Mutation Identified in Lethal Acantholytic Epidermolysis Bullosa. Journal of Investigative Dermatology, 2010, 130, 2680-2683.	0.7	33
212	A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents. JAMA Dermatology, 2020, 156, 384.	4.1	33
213	Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. American Journal of Clinical Dermatology, 2021, 22, 101-115.	6.7	32
214	Guidelines of care for neurofibromatosis type 1. Journal of the American Academy of Dermatology, 1997, 37, 625-630.	1.2	31
215	Ongoing blistering in a boy with congenital erosive and vesicular dermatosis healing with reticulated supple scarring. Journal of the American Academy of Dermatology, 2001, 45, 946-948.	1.2	31
216	Ganglioside Modulation Regulates Epithelial Cell Adhesion and Spreading via Ganglioside-specific Effects on Signaling. Journal of Biological Chemistry, 2002, 277, 40410-40419.	3.4	31

#	Article	IF	Citations
217	De-N-acetyl GM3 Promotes Melanoma Cell Migration and Invasion through Urokinase Plasminogen Activator Receptor Signalingâ€“Dependent MMP-2 Activation. Cancer Research, 2009, 69, 8662-8669.	0.9	31
218	Clinical Pearl: Use of self-adhesive, compressive wraps in the treatment of limb hemangiomas. Journal of the American Academy of Dermatology, 1995, 32, 117-118.	1.2	30
219	Ganglioside Loss Promotes Survival Primarily by Activating Integrin-Linked Kinase/Akt Without Phosphoinositide 3-OH Kinase Signaling. Journal of Investigative Dermatology, 2002, 119, 107-117.	0.7	30
220	Accelerated T-cell activation and differentiation of polar subsets characterizes early atopic dermatitis development. Journal of Allergy and Clinical Immunology, 2016, 138, 1473-1477.e5.	2.9	30
221	A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatric Dermatology, 2019, 36, 290-297.	0.9	30
222	Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). American Journal of Clinical Dermatology, 2022, 23, 365-383.	6.7	30
223	Ganglioside GT1b Inhibits Keratinocyte Adhesion and Migration on a Fibronectin Matrix. Journal of Investigative Dermatology, 1995, 105, 237-242.	0.7	29
224	Congenital erosive and vesicular dermatosis with reticulated supple scarring: Unifying clinical features. Journal of the American Academy of Dermatology, 2013, 69, 909-915.	1.2	29
225	The role of abnormalities in the distal pathway of cholesterol synthesis in the Congenital Hemidysplasia with Ichthyosiform erythroderma and Limb Defects (CHILD) syndrome. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 345-352.	2.4	29
226	SARSâ€CoVâ€2 receptor ACE2 protein expression in serum is significantly associated with age. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 875-878.	5.7	29
227	T-Lymphocyte Subsets in the Lesional Skin of Allogeneic and Autologous Bone Marrow Transplant Patients. Archives of Dermatology, 1988, 124, 1795.	1.4	28
228	Evaluation of Treatments for Pruritus in Epidermolysis Bullosa. Pediatric Dermatology, 2015, 32, 628-634.	0.9	28
229	Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. Journal of the American Academy of Dermatology, 2020, 82, 389-397.	1.2	28
230	Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1432-1449.	2.4	28
231	Integrin Î±5Î²1 Expression Is Required for Inhibition of Keratinocyte Migration by Ganglioside GT1b. Experimental Cell Research, 1998, 239, 311-319.	2.6	27
232	Mind the Gap: Sex Bias in Basic Skin Research. Journal of Investigative Dermatology, 2016, 136, 12-14.	0.7	27
233	Risk of intraocular and other extracutaneous involvement in patients with cutaneous juvenile xanthogranuloma. Pediatric Dermatology, 2018, 35, 329-335.	0.9	27
234	Systematic Review and Meta-analysis Comparing Topical Corticosteroids With Vehicle/Moisturizer in Childhood Atopic Dermatitis. Journal of Pediatric Nursing, 2019, 47, 36-43.	1.5	27

#	Article	IF	Citations
235	Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America. JAMA Dermatology, 2019, 155, 196.	4.1	27
236	Ganglioside GM3 Promotes Carcinoma Cell Proliferation via Urokinase Plasminogen Activator-Induced Extracellular Signal-Regulated Kinase-Independent p70S6 Kinase Signaling. Journal of Investigative Dermatology, 2006, 126, 2687-2696.	0.7	26
237	Practical management of cutaneous reactions to the methylphenidate transdermal system: Recommendations from a dermatology expert panel consensus meeting. Clinical Therapeutics, 2008, 30, 326-337.	2.5	26
238	Effect of cat and daycare exposures on the risk of asthma in children with atopic dermatitis. Allergy and Asthma Proceedings, 2012, 33, 282-288.	2.2	26
239	Pseudoporphyria cutanea tarda: Two case reports on children receiving peritoneal dialysis and erythropoietin therapy. Journal of Pediatrics, 1992, 121, 749-752.	1.8	25
240	Cracks in the foundation: keratin filaments and genetic disease. Trends in Cell Biology, 1994, 4, 321-326.	7.9	25
241	Commentary: â€œLeaning inâ€•to Support Sex Differences in Basic Science and Clinical Research. Endocrinology, 2014, 155, 1181-1183.	2.8	25
242	Temporal and Racial Differences Associated with Atopic Dermatitis Staphylococcus aureus and Encoded Virulence Factors. MSphere, 2016, 1, .	2.9	25
243	Bacterial colonization, overgrowth, and superinfection in atopic dermatitis. Clinics in Dermatology, 2018, 36, 641-647.	1.6	25
244	"Free-Floating" Desmosomes in Lipoid Proteinosis: An Inherent Defect in Keratinocyte Adhesion?. Pediatric Dermatology, 2006, 23, 1-6.	0.9	24
245	Pathogenesis of the cutaneous phenotype in inherited disorders of cholesterol metabolism. Dermato-Endocrinology, 2011, 3, 100-106.	1.8	24
246	Vitamin D deficiency and rickets in children and adolescents with ichthyosiform erythroderma in type IV and V skin. British Journal of Dermatology, 2012, 166, 608-615.	1.5	24
247	Making a Mountain Out of a Molehill: NRAS, Mosaicism, and Large Congenital Nevi. Journal of Investigative Dermatology, 2013, 133, 2127-2130.	0.7	24
248	Use of dupilimab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis. Pediatric Dermatology, 2019, 36, 172-176.	0.9	24
249	Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis. Journal of Drugs in Dermatology, 2018, 17, 187-194.	0.8	24
250	Primary Cutaneous T-cell Lymphoma in a Child. Pediatric Dermatology, 1984, 2, 131-135.	0.9	23
251	Graft-versus-host disease following ECMO. Journal of Pediatric Surgery, 1991, 26, 317-319.	1.6	23
252	Laboratory Tests for Ichthyosis. Dermatologic Clinics, 1994, 12, 99-107.	1.7	23

#	Article	IF	Citations
253	Use of nonsteroidal topical immunomodulators for the treatment of atopic dermatitis in the pediatric population. Journal of Pediatrics, 2001, 138, 163-168.	1.8	23
254	Score of Toxic Epidermal Necrosis Predicts the Outcomes of Pediatric Epidermal Necrolysis. Pediatric Dermatology, 2017, 34, 433-437.	0.9	23
255	Epidermolysis Bullosa Simplex with KLHL24 Mutations Is Associated with Dilated Cardiomyopathy. Journal of Investigative Dermatology, 2019, 139, 244-249.	0.7	23
256	Sleep Disturbance in School-Aged Children with Atopic Dermatitis: Prevalence and Severity in a Cross-Sectional Sample. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3120-3129.e3.	3.8	23
257	Piecing together the puzzle of cutaneous mosaicism. Journal of Clinical Investigation, 2004, 114, 1407-1409.	8.2	23
258	Psoriasiform dermatitis during dupilumab treatment for moderateâ€toâ€severe atopic dermatitis in children. Pediatric Dermatology, 2021, 38, 1500-1505.	0.9	23
259	Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitisâ€”A pooled analysis of trial data. Pediatric Dermatology, 2022, 39, 187-196.	0.9	23
260	What Syndrome Is This?. Pediatric Dermatology, 1997, 14, 403-405.	0.9	22
261	Expanding Our Concepts of Mosaic Disorders of Skin. Archives of Dermatology, 2001, 137, 1236-8.	1.4	22
262	Safe treatment of head/neck AD with Tacrolimus ointment. Journal of Dermatological Treatment, 2003, 14, 86-94.	2.2	22
263	Visualization of Sensory Neurons and Their Projections in an Upper Motor Neuron Reporter Line. PLoS ONE, 2015, 10, e0132815.	2.5	22
264	Topically Delivered Tumor Necrosis Factor-Î±â€“Targeted Gene Regulation forÂPsoriasis. Journal of Investigative Dermatology, 2017, 137, 2027-2030.	0.7	22
265	Ganglioside GM3 Mediates Glucose-Induced Suppression of IGF-1 Receptorâ€“Rac1 Activation to Inhibit Keratinocyte Motility. Journal of Investigative Dermatology, 2017, 137, 440-448.	0.7	22
266	Replicated methylation changes associated with eczema herpeticum and allergic response. Clinical Epigenetics, 2019, 11, 122.	4.1	22
267	Sodium hypochlorite body wash in the management of Staphylococcus aureusâ€“colonized moderateâ€toâ€severe atopic dermatitis in infants, children, and adolescents. Pediatric Dermatology, 2019, 36, 442-447.	0.9	22
268	Treatment patterns of pediatric patients with atopic dermatitis: A claims data analysis. Journal of the American Academy of Dermatology, 2020, 82, 651-660.	1.2	22
269	Supportive care in the acute phase of Stevensâ€“Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphiâ€based consensus. British Journal of Dermatology, 2021, 185, 616-626.	1.5	22
270	Treatment Strategies for Atopic Dermatitis: Optimizing the Available Therapeutic Options. Seminars in Cutaneous Medicine and Surgery, 2012, 31, S10-S17.	1.6	21

#	Article	IF	Citations
271	Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. American Journal of Clinical Dermatology, 2019, 20, 711-723.	6.7	21
272	Profiling ImmuneÂExpression to Consider Repurposing Therapeutics for the Ichthyoses. Journal of Investigative Dermatology, 2019, 139, 535-540.	0.7	21
273	Compound Heterozygous Mutations in the Hairless Gene in Atrichia with Papular Lesions. Journal of Investigative Dermatology, 2003, 121, 430-432.	0.7	20
274	Leukotriene receptor antagonists are ineffective for severe atopic dermatitis. Journal of the American Academy of Dermatology, 2004, 50, 485-486.	1.2	20
275	Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children. Journal of the American Academy of Dermatology, 2020, 82, 1187-1194.	1.2	20
276	Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2510-2523.	5.7	20
277	The Genomic and Phenotypic Landscape of Ichthyosis. JAMA Dermatology, 2022, 158, 16.	4.1	20
278	Localization of the Alpha 3 (V) Chain of Type V Collagen in Human Skin. Journal of Investigative Dermatology, 1987, 88, 246-252.	0.7	19
279	Ganglioside GT1b Induces Keratinocyte Differentiation without Activating Protein Kinase C. Experimental Cell Research, 1995, 217, 118-124.	2.6	19
280	Lipid Rafts: Membrane Triage Centers. Journal of Investigative Dermatology, 2006, 126, 951-953.	0.7	19
281	Current Issues in Atopic Comorbidities and Preventing the Atopic March. Seminars in Cutaneous Medicine and Surgery, 2012, 31, S6-S9.	1.6	19
282	Phenotypic spectrum of autosomal recessive congenital ichthyosis due to PNPLA1 mutation. British Journal of Dermatology, 2017, 177, 319-322.	1.5	19
283	Inefficacy of oral cimetidine for nonatopic children with molluscum contagiosum [letter; comment]. Pediatric Dermatology, 1998, 15, 71-72.	0.9	19
284	Livedo Reticularis in a Child with Moyamoya Disease. Pediatric Dermatology, 2003, 20, 124-127.	0.9	18
285	Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. British Journal of Dermatology, 2007, 157, 378-381.	1.5	18
286	Headaches as a Presenting Symptom of Linear Morphea en Coup de Sabre. Pediatrics, 2014, 134, e1715-e1719.	2.1	18
287	Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families. Dermatology and Therapy, 2018, 8, 605-619.	3.0	18
288	Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. American Journal of Clinical Dermatology, 2021, 22, 243-255.	6.7	18

#	Article	IF	Citations
289	Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma. Journal of the American Academy of Dermatology, 2010, 63, e58-e59.	1.2	17
290	Ganglioside GM3 synthase depletion reverses neuropathic pain and small fiber neuropathy in diet-induced diabetic mice. Molecular Pain, 2016, 12, 174480691666628.	2.1	17
291	Expanding the Genotypic Spectrum of Bathing Suit Ichthyosis. JAMA Dermatology, 2017, 153, 537.	4.1	17
292	Rapid Capture and Extraction of Sweat for Regional Rate and Cytokine Composition Analysis Using a Wearable Soft Microfluidic System. Journal of Investigative Dermatology, 2021, 141, 433-437.e3.	0.7	17
293	Characterization of wound microbes in epidermolysis bullosa: Results from the epidermolysis bullosa clinical characterization and outcomes database. Pediatric Dermatology, 2021, 38, 119-124.	0.9	17
294	Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis. JAMA Dermatology, 2022, 158, 533.	4.1	17
295	Leukocyte adhesion deficiency: Recurrent childhood skin infections. Journal of the American Academy of Dermatology, 1994, 31, 316-319.	1.2	16
296	The Use of Pulse Corticosteroid Therapy for Juvenile Dermatomyositis. Pediatric Dermatology, 1996, 13, 347-348.	0.9	16
297	Raised limb bands developing in infancy. British Journal of Dermatology, 2003, 149, 436-437.	1.5	16
298	Developing drugs for treatment of atopic dermatitis in children (â‰¥3 months to <18 years of age): Draft guidance for industry. Pediatric Dermatology, 2018, 35, 303-322.	0.9	16
299	Defining and measuring â€˜eczema controlâ€™: an international qualitative study to explore the views of those living with and treating atopic eczema. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1124-1132.	2.4	16
300	Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice. American Journal of Clinical Dermatology, 2020, 21, 579-590.	6.7	16
301	Management of Severe Atopic Dermatitis in Pediatric Patients. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1462-1471.	3.8	16
302	Effects of variations in access to care for children with atopic dermatitis. BMC Dermatology, 2020, 20, 24.	2.1	16
303	Secukinumab responses vary across the spectrum of congenital ichthyosis in adults. Archives of Dermatological Research, 2023, 315, 305-315.	1.9	16
304	Absence of a Stratum Corneum Antigen in Disorders of Epidermal Cell Proliferation: Detection with an Anti-Ganglioside GM3 Antibody. Journal of Investigative Dermatology, 1989, 92, 240-246.	0.7	15
305	Cutaneous Fusarium Infection in an Adolescent with Acute Leukemia. Pediatric Dermatology, 1992, 9, 62-65.	0.9	15
306	Efficacy andÂsafety ofÂetanercept inÂchildren andÂadolescents agedâ‰¥8Âyears withÂsevere plaque psoriasis. European Journal of Dermatology, 2010, 20, 323-328.	0.6	15

#	Article	IF	Citations
307	Gangliosides in Diabetic Wound Healing. Progress in Molecular Biology and Translational Science, 2018, 156, 229-239.	1.7	15
308	Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council surveyâ€based position statement. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 807-815.	2.4	15
309	Topical therapy of atopic dermatitis with a focus on pimecrolimus. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1505-1518.	2.4	15
310	CARD14â€associated papulosquamous eruption (CAPE) in pediatric patients: Three additional cases and review of the literature. Pediatric Dermatology, 2021, 38, 1237-1242.	0.9	15
311	Laboratory Safety of Dupilumab in Patients Aged 6â€“11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. Paediatric Drugs, 2021, 23, 515-527.	3.1	15
312	Multiethnic genome-wide and HLA association study of total serum IgE level. Journal of Allergy and Clinical Immunology, 2021, 148, 1589-1595.	2.9	15
313	A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. Archives of Dermatological Research, 2022, , .	1.9	15
314	Knuckle Pads in Children. JAMA Pediatrics, 1986, 140, 915.	3.0	14
315	Chediak-Higashi Syndrome in a Black Child. Pediatric Dermatology, 1992, 9, 31-36.	0.9	14
316	The Yin and the Yang of Keratin Amino Acid Substitutions and Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2011, 131, 1787-1790.	0.7	14
317	Hermanskyâ€Pudlak syndrome: Report of two patients with updated genetic classification and management recommendations. Pediatric Dermatology, 2017, 34, 638-646.	0.9	14
318	Histopathologic findings characteristic of CARD14â€associated papulosquamous eruption. Journal of Cutaneous Pathology, 2020, 47, 425-430.	1.3	14
319	Early development of the skin microbiome: therapeutic opportunities. Pediatric Research, 2021, 90, 731-737.	2.3	14
320	Acral Changes in pediatric patients during COVID 19 pandemic: Registry report from the COVID 19 response task force of the society of pediatric dermatology (SPD) and pediatric dermatology research alliance (PeDRA). Pediatric Dermatology, 2021, 38, 364-370.	0.9	14
321	Skin disease is more recalcitrant than muscle disease: A long-term prospective study of 184 children with juvenile dermatomyositis. Journal of the American Academy of Dermatology, 2021, 84, 1610-1618.	1.2	14
322	Dermatologic Uses of Methotrexate in Children: Indications and Guidelines. Pediatric Dermatology, 1985, 2, 238-243.	0.9	13
323	Responses to Anti-Angiogenic Therapies. Journal of Investigative Dermatology Symposium Proceedings, 2000, 5, 83-86.	0.8	13
324	Unexpected Occurrence of Xeroderma Pigmentosum in an Uncle and Nephew. Archives of Dermatology, 2009, 145, 1285-91.	1.4	13

#	Article	IF	Citations
325	Deacetylated GM3 Promotes uPAR-Associated Membrane Molecular Complex to Activate p38 MAPK in Metastatic Melanoma. Molecular Cancer Research, 2013, 11, 665-675.	3.4	13
326	Mutations in ASPRV1 Cause Dominantly Inherited Ichthyosis. American Journal of Human Genetics, 2020, 107, 158-163.	6.2	13
327	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADâ„¢): a clinical outcome measure for the severity of atopic dermatitis. British Journal of Dermatology, 2022, 187, 531-538.	1.5	13
328	Pedal hemangiomas in Turner syndrome. Journal of Pediatrics, 1983, 103, 87-88.	1.8	12
329	Intertriginous pustular psoriasis. Journal of the American Academy of Dermatology, 2009, 60, 679-683.	1.2	12
330	Neurocognitive function in moderateâ€“severe pediatric atopic dermatitis: A caseâ€“control study. Pediatric Dermatology, 2019, 36, 110-114.	0.9	12
331	Loss-of-function variants in C3ORF52 result in localized autosomal recessive hypotrichosis. Genetics in Medicine, 2020, 22, 1227-1234.	2.4	12
332	Pathogenesis-Based Therapy With Repurposed Biologics for Monogenic Inflammatory Skin Disorders. JAMA Dermatology, 2020, 156, 839.	4.1	12
333	Topical calcineurin inhibitors for pediatric periorificial dermatitis. Journal of the American Academy of Dermatology, 2020, 82, 1409-1414.	1.2	12
334	Cutaneous Sarcoidosis Associated With Sarcoidosis of the Upper Airway. Archives of Dermatology, 1983, 119, 592.	1.4	11
335	Eosinophilic Pustular Folliculitis in Infancy and Childhood. JAMA Pediatrics, 1993, 147, 197.	3.0	11
336	Epidermal necrosis with multinucleated keratinocytes: a possible diagnostic clue for dermatitis artefacta in children. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e101-e102.	2.4	11
337	A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2017, 139, 1575-1582.e8.	2.9	11
338	Epidermolytic Ichthyosis Sine Epidermolysis. American Journal of Dermatopathology, 2017, 39, 440-444.	0.6	11
339	Severity assessments used for inclusion criteria and baseline severity evaluation in atopic dermatitis clinical trials: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1890-1899.	2.4	11
340	Association between the longitudinal course of AD, sleep disturbance, and overall health in US children. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 812-814.e1.	3.8	11
341	Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensusâ€based guidance for clinical decisionâ€making during the COVIDâ€19 pandemic. Pediatric Dermatology, 2020, 37, 424-434.	0.9	11
342	Targeted Therapy for Pediatric Psoriasis. Paediatric Drugs, 2021, 23, 203-212.	3.1	11

#	Article	IF	Citations
343	Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors. Journal of Allergy and Clinical Immunology, 2022, 149, 145-155.	2.9	11
344	Biologics for pediatric psoriasis: A systematic review and metaâ€analysis. Pediatric Dermatology, 2022, 39, 42-48.	0.9	11
345	Transcriptomic Analysis of the Major Orphan Ichthyosis Subtypes Reveals Shared Immune and Barrier Signatures. Journal of Investigative Dermatology, 2022, 142, 2363-2374.e18.	0.7	11
346	Distinct skin microbiome community structures in congenital ichthyosis. British Journal of Dermatology, 2022, 187, 557-570.	1.5	11
347	Tape strips capture atopic dermatitisâ€related changes in nonlesional skin throughout maturation. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3445-3447.	5.7	11
348	Pigmentary Patterning as a Clinical Clue of Genetic Mosaicism. Archives of Dermatology, 1996, 132, 1234.	1.4	10
349	The Molecular Bases for the Palmoplantarâ€ƒKeratodermas. Pediatric Dermatology, 1999, 16, 483-486.	0.9	10
350	The Economics of Topical Immunomodulators for the Treatment of Atopic Dermatitis. Pharmacoeconomics, 2005, 23, 543-566.	3.3	10
351	Tretinoin Microsphere Gel 0.04% Pump for Treating Acne Vulgaris in Preadolescents: A Randomized, Controlled Study. Pediatric Dermatology, 2012, 29, 598-604.	0.9	10
352	Improving the Patient-Clinician and Parent-Clinician Partnership in Atopic Dermatitis Management. Seminars in Cutaneous Medicine and Surgery, 2012, 31, S23-S28.	1.6	10
353	Pathogenesis-based therapies in ichthyoses. Dermatologic Therapy, 2013, 26, 46-54.	1.7	10
354	Potential impact of biologics and emerging therapies for psoriasis and atopic dermatitis on future fertility: Reassurance to patients but more data are needed. Journal of the American Academy of Dermatology, 2017, 77, 758-763.	1.2	10
355	Adverse events reported to the Food and Drug Administration from 2004 to 2016 for cosmetics and personal care products marketed to newborns and infants. Pediatric Dermatology, 2018, 35, 225-229.	0.9	10
356	Cutaneous Disorders of the Newborn. , 2011, , 10-36.		10
357	Piecing together the puzzle of cutaneous mosaicism. Journal of Clinical Investigation, 2004, 114, 1407-1409.	8.2	10
358	Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence Study. Acta Dermato-Venereologica, 2021, 102, adv00660.	1.3	10
359	Self-Reported Health Outcomes of Children and Youth with 10 Chronic Diseases. Journal of Pediatrics, 2022, 246, 207-212.e1.	1.8	10
360	Optimizing topical management of atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2022, 128, 488-504.	1.0	10

#	Article	IF	Citations
361	Atrophie blanche with onset in childhood. Journal of Pediatrics, 1993, 123, 753-755.	1.8	9
362	Latest Approaches to Treating Atopic Dermatitis. Chemical Immunology and Allergy, 2012, 96, 132-140.	1.7	9
363	Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis. Journal of Clinical Pharmacology, 2018, 58, 340-346.	2.0	9
364	Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study. Orphanet Journal of Rare Diseases, 2020, 15, 190.	2.7	9
365	Patient-reported outcomes for measuring sleep disturbance in pediatric atopic dermatitis: Cross-sectional study of the Patient Reported Outcomes Measurement Information System pediatric sleep measures and actigraphy. Journal of the American Academy of Dermatology, 2023, 88, 348-356.	1.2	9
366	Characterization of CYP26B1-Selective Inhibitor, DX314, as a Potential Therapeutic for Keratinization Disorders. Journal of Investigative Dermatology, 2021, 141, 72-83.e6.	0.7	9
367	Characteristics and impacts of itch in children with inflammatory skin disorders*. British Journal of Dermatology, 2021, 184, 896-904.	1.5	9
368	The atopic march and its prevention. Annals of Allergy, Asthma and Immunology, 2021, 127, 289-290.	1.0	9
369	What Syndrome Is This?. Pediatric Dermatology, 2001, 18, 252-254.	0.9	9
370	Subgroup analyses of etanercept in pediatric patients with psoriasis. Journal of the American Academy of Dermatology, 2010, 63, e38-e41.	1.2	8
371	Patient Satisfaction and Quality of Life in Psoriasis and Psoriatic Arthritis. JAMA - Journal of the American Medical Association, 2014, 312, 2676.	7.4	8
372	Treatment of symptomatic epidermolysis bullosa simplex with botulinum toxin in a pediatric patient. JAAD Case Reports, 2016, 2, 259-260.	0.8	8
373	Mycophenolate Mofetil and Mood Changes in Children with Skin Disorders. Pediatric Dermatology, 2016, 33, e216-7.	0.9	8
374	Oligonucleotide Molecular Sprinkler for Intracellular Detection and Spontaneous Regulation of mRNA for Theranostics of Scar Fibroblasts. Small, 2018, 14, e1802546.	10.0	8
375	Folic acid functionalized hollow nanoparticles for selective photodynamic therapy of cutaneous squamous cell carcinoma. Materials Chemistry Frontiers, 2019, 3, 1113-1122.	5.9	8
376	Practiceâ€based differences in paediatric discoid lupus erythematosus. British Journal of Dermatology, 2019, 181, 805-810.	1.5	8
377	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open, 2020, 10, e039928.	1.9	8
378	Flotillin and AP2A1/2 Promote IGF-1 Receptor Association with Clathrin and Internalization in Primary Human Keratinocytes. Journal of Investigative Dermatology, 2020, 140, 1743-1752.e4.	0.7	8

#	Article	IF	Citations
379	Pediatric maculopapular cutaneous mastocytosis: Retrospective review of signs, symptoms, and associated conditions. Pediatric Dermatology, 2021, 38, 159-163.	0.9	8
380	Use of technology for the objective evaluation of scratching behavior: A systematic review. JAAD International, 2021, 5, 19-32.	2.2	8
381	New therapies for atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2022, 128, 344-345.	1.0	8
382	What Syndrome Is This?. Pediatric Dermatology, 1996, 13, 63-64.	0.9	7
383	Introducing a curriculum in ethics and professionalism for dermatology residencies. Journal of the American Academy of Dermatology, 2018, 78, 1032-1034.	1.2	7
384	Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemicâ€"Consensus: Recommendations by an international panel of experts. Journal of the American Academy of Dermatology, 2020, 83, 1222-1224.	1.2	7
385	Gene Regulation Using Spherical Nucleic Acids to Treat Skin Disorders. Pharmaceuticals, 2020, 13, 360.	3.8	7
386	Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study). Orphanet Journal of Rare Diseases, 2020, 15, 158.	2.7	7
387	Body site distribution of pediatric-onset morphea and association with extracutaneous manifestations. Journal of the American Academy of Dermatology, 2021, 85, 38-45.	1.2	7
388	Vascular Disorders of Infancy and Childhood. , 2011, , 268-302.		7
389	Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: Real-world evidence. Journal of the American Academy of Dermatology, 2022, 86, 758-765.	1.2	7
390	Efficacy and Safety of Topical Nitric Oxideâ^'Releasing Berdazimer Gel in Patients With Molluscum Contagiosum. JAMA Dermatology, 0, , .	4.1	7
391	Nocturnal movements in children with atopic dermatitis have a timing pattern: A case-control study. Journal of the American Academy of Dermatology, 2021, 85, 474-476.	1.2	6
392	Neurocognitive dysfunction and anaphylaxis in pediatric maculopapular cutaneous mastocytosis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 409-410.	3.8	6
393	Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology. BMJ Open, 2020, 10, e033507.	1.9	6
394	Epidermal SR-A Complexes Are Lipid Raft Based and Promote Nucleic Acid Nanoparticle Uptake. Journal of Investigative Dermatology, 2021, 141, 1428-1437.e8.	0.7	6
395	The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis. Clinical Pharmacology and Therapeutics, 2021, 110, 1318-1328.	4.7	6
396	Population pharmacokinetic and exposureâ€"efficacy analysis of ixekizumab in paediatric patients with moderateâ€toâ€severe plaque psoriasis (IXORAâ€PEDS). British Journal of Clinical Pharmacology, 2022, 88, 1074-1086.	2.4	6

#	Article	IF	Citations
397	Generation and Validation of the Patient-Reported Outcome Measurement Information System Itch Questionnaireâ€“Child (PIQ-C) to Measure the Impact of Itch on Life Quality. Journal of Investigative Dermatology, 2022, 142, 1309-1317.e1.	0.7	6
398	Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12Âyears old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry. Journal of the American Academy of Dermatology, 2022, 87, 1104-1108.	1.2	6
399	Cytokine induced 3â€D organotypic psoriasis skin model demonstrates distinct roles for NFâ€ºB and JAK pathways in disease pathophysiology. Experimental Dermatology, 2022, 31, 1036-1047.	2.9	6
400	Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study. Journal of the American Academy of Dermatology, 2022, 87, 1189-1191.	1.2	6
401	Genetic Disorders of Skin. Archives of Dermatology, 2003, 139, 74.	1.4	5
402	Genetic Immunodeficiency Diseases. Advances in Dermatology, 2007, 23, 197-229.	2.0	5
403	Impediments to Research in Pediatric Dermatology: The Results of a Survey of the Members of the Society for Pediatric Dermatology. Pediatric Dermatology, 2010, 27, 337-340.	0.9	5
404	Eczema, Atopic Dermatitis, or Atopic Eczema: Analysis of Global Search Engine Trends. Dermatitis, 2017, 28, 276-279.	1.6	5
405	Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mildâ€toâ€moderate atopic dermatitis. Pediatric Dermatology, 2020, 37, 1030-1037.	0.9	5
406	Collagen Vascular Disorders. , 2011, , 497-527.		5
407	Targeted therapies for pediatric psoriasis. Seminars in Cutaneous Medicine and Surgery, 2018, 37, 167-172.	1.6	5
408	IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis*. British Journal of Dermatology, 2022, 186, 496-507.	1.5	5
409	Extensive Ichthyosiform Sarcoidosis in a Patient With Juvenile Rheumatoid Arthritis. Archives of Dermatology, 1985, 121, 171.	1.4	4
410	DERMATOLOGIC CLUES TO INHERITED DISEASE. Pediatric Clinics of North America, 2000, 47, 825-839.	1.8	4
411	Genetic immunodeficiency disorders. Clinics in Dermatology, 2005, 23, 68-77.	1.6	4
412	Neurotoxicity in the setting of pediatric atopic dermatitis treated with modified cyclosporine and itraconazole. Journal of the American Academy of Dermatology, 2013, 69, e177-e178.	1.2	4
413	Eruptive Xanthomas Masquerading as Molluscum Contagiosum. Pediatrics, 2014, 134, e257-e260.	2.1	4
414	Optimizing Clinical Trials for Atopic Dermatitis in Children. Journal of Investigative Dermatology, 2017, 137, 1363-1364.	0.7	4

#	Article	IF	Citations
415	A march by any other name. Annals of Allergy, Asthma and Immunology, 2018, 121, 137-138.	1.0	4
416	Update on pachyonychia congenita research. British Journal of Dermatology, 2020, 182, 788-789.	1.5	4
417	Attenuation of Abnormal Scarring Using Spherical Nucleic Acids Targeting Transforming Growth Factor Beta 1. ACS Applied Bio Materials, 2020, 3, 8603-8610.	4.6	4
418	Hereditary Disorders of Cornification. , 2011, , 92-114.		4
419	Timing of itch among children with atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2022, 128, 603-605.	1.0	4
420	Development and Initial Validation of a Novel System to Assess Ichthyosis Severity. JAMA Dermatology, 2022, 158, 359.	4.1	4
421	Parent report of sleep health and attention regulation in a crossâ€sectional study of infants and preschoolâ€aged children with atopic dermatitis. Pediatric Dermatology, 2022, 39, 61-68.	0.9	4
422	Bullous Disorders of Childhood. , 2016, , 317-333.e5.		4
423	Photosensitivity and Photoreactions. , 2016, , 448-466.e4.		4
424	Bleach baths for atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2022, 128, 617-618.	1.0	4
425	Infants With "Hair Today That's Gone Tomorrow". Archives of Dermatology, 2003, 139, 1644-5.	1.4	3
426	GLI1 genotypes do not predict basal cell carcinoma risk: a case control study. Molecular Cancer, 2009, 8, 113.	19.2	3
427	Out of the Skin of Babes: Measuring the Full Impact of Atopic Dermatitis in Infants and Young Children. Journal of Investigative Dermatology, 2012, 132, 2494-2496.	0.7	3
428	Ruth Kimmelstiel Freinkel (1926â€“2014). Journal of Investigative Dermatology, 2014, 134, 2669-2670.	0.7	3
429	Interstitial lung disease in STING-associated vasculopathy with onset in infancy (SAVI): preliminary genotype-phenotype correlation. Pediatric Rheumatology, 2015, 13, .	2.1	3
430	Sex-Based Biomedical Research Policy Needs an Implementation Plan. Women's Health, 2015, 11, 449-452.	1.5	3
431	Which Nanobasics Should Be Taught in Medical Schools?. AMA Journal of Ethics, 2019, 21, E337-346.	0.7	3
432	Can a handheld device accurately measure barrier function in ichthyoses?. Pediatric Dermatology, 2020, 37, 860-863.	0.9	3

#	Article	IF	Citations
433	Transepidermal water loss in the orphan forms of ichthyosis. Pediatric Dermatology, 2020, 37, 771-773.	0.9	3
434	Pigmented purpuric dermatosis in children: a retrospective cohort with emphasis on treatment and outcomes. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2402-2408.	2.4	3
435	Incorporating joint pain screening into the pediatric dermatologic examination. Pediatric Dermatology, 2021, 38, 92-97.	0.9	3
436	Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus. British Journal of Dermatology, 2021, 185, 203-205.	1.5	3
437	Viral Diseases of the Skin. , 2011, , 348-369.		3
438	Update on selected inherited immunodeficiency syndromes. Seminars in Dermatology, 1995, 14, 60-65.	0.6	3
439	Inherited disorders of keratinization. Current Problems in Dermatology, 2002, 014, 71-116.	0.0	3
440	Methylphenidate Transdermal System. Primary Care Companion To the Journal of Clinical Psychiatry, 2010, 12, .	0.6	3
441	A retrospective analysis of diagnostic testing in a large North American cohort of patients with epidermolysis bullosa. Journal of the American Academy of Dermatology, 2021, , .	1.2	3
442	The relationship between obesity and psoriasis in the pediatric population: implications and future directions. Cutis, 2013, 92, 107-9.	0.3	3
443	Burden and characteristics of skin pain among children with atopic dermatitis. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1104-1106.e1.	3.8	3
444	Hereditary Disorders of Cornification. , 2016, , 95-118.e8.		3
445	Cross-sectional characteristics of pediatric-onset discoid lupus erythematosus: Results of a multicenter, retrospective cohort study. Journal of the American Academy of Dermatology, 2022, 87, 559-566.	1.2	3
446	Eczematous Eruptions in Childhood. , 2016, , 38-72.e7.		3
447	Vascular Disorders of Infancy and Childhood. , 2016, , 279-316.e6.		3
448	Papulosquamous and Related Disorders. , 2016, , 73-94.e4.		3
449	Three-Question Skindex-Mini Measures Quality of Life in Children with Atopic Dermatitis. Journal of the American Academy of Dermatology, 2022, , .	1.2	3
450	Stump the Experts. Dermatologic Surgery, 1995, 21, 361-362.	0.8	2

#	Article	IF	Citations
451	Stump the Experts. Dermatologic Surgery, 1995, 21, 284.	0.8	2
452	Nano-Based Gene Therapy for Dermatologic Diseases. , 2013, , 109-117.		2
453	Oral Macrolides for the Dermatologic Manifestations of Blau Syndrome. JAMA Dermatology, 2017, 153, 1066.	4.1	2
454	Topical Hypochlorite and Skin Acidification Improves Erythroderma of Omenn Syndrome. Pediatrics, 2018, 141, S408-S411.	2.1	2
455	Vaccines do not cause atopic dermatitis: A systematic review and meta-analysis. Vaccine, 2021, 39, 1805-1811.	3.8	2
456	Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders. Skin Health and Disease, 2021, 1, e22.	1.5	2
457	Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderateâ€toâ€severe psoriasis: a post hoc analysis from IXORAâ€PEDS. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e911-e913.	2.4	2
458	Disorders of Hair and Nails. , 2016, , 136-174.e9.		2
459	Histiocytoses and Malignant Skin Diseases. , 2011, , 219-233.		2
460	The Hypersensitivity Syndromes. , 2011, , 454-482.		2
461	Skin Signs of Other Systemic Diseases. , 2011, , 562-579.		2
462	Eczematous Eruptions in Childhood. , 2011, , 37-70.		2
463	Disorders of Pigmentation. , 2011, , 234-267.		2
464	Papulosquamous and Related Disorders. , 2011, , 71-91.		2
465	Disorders of Hair and Nails. , 2011, , 130-166.		2
466	Single-question parent-reported global atopic dermatitis severity: A valid instrument in children. Journal of the American Academy of Dermatology, 2023, 88, 212-215.	1.2	2
467	Skin Signs of Other Systemic Diseases. , 2016, , 573-591.e6.		2
468	The Hypersensitivity Syndromes. , 2016, , 467-494.e6.		2

#	Article	IF	Citations
469	Inherited disorders of keratinization. Current Problems in Dermatology, 2002, 14, 77-115.	0.0	1
470	Congenital hypertrichotic melanoneurocytoma: AÂcongenital hypertrichotic plaque with overlapping neural and nevoid features. Journal of the American Academy of Dermatology, 2012, 67, 799-801.	1.2	1
471	Clarification of methodology and further results from the pivotal phase 3 study of crisaborole for mild-moderate atopic dermatitis. British Journal of Dermatology, 2018, 178, 663-664.	1.5	1
472	Response to â€œComment on: â€˜When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Councilâ€™â€•. Journal of the American Academy of Dermatology, 2018, 79, e25-e26.	1.2	1
473	Reply to â€œCombined antibiotic, steroid, and moisturizer for atopic dermatitis: A 2â€year case series of patientâ€reported outcomesâ€• Pediatric Dermatology, 2021, 38, 736-737.	0.9	1
474	Disorders of Cornification (Ichthyosis). , 2008, , 285-310.		1
475	Cutaneous Tumors and Tumor Syndromes. , 2011, , 184-218.		1
476	Photosensitivity and Photoreactions. , 2011, , 436-453.		1
477	Laryngo-Onycho-Cutaneous Syndrome. , 2015, , 393-396.		1
478	Juvenile Localized and Systemic Scleroderma. , 2017, , 75-89.		1
479	Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6ÂYears of Age and Older. Dermatology and Therapy, 2021, 11, 1643-1656.	3.0	1
480	Histiocytoses and Malignant Skin Diseases. , 2016, , 230-244.e3.		1
481	Cutaneous Disorders of the Newborn. , 2016, , 11-37.e4.		1
482	Hereditary Disorders of the Dermis. , 2016, , 119-135.e6.		1
483	Viral Diseases of the Skin. , 2016, , 360-381.e3.		1
484	The Discrimination Between CD8+ Cytotoxic and CD8+ Suppressor Lymphocyte Subsets Within Cutaneous Infiltrates-Reply. Archives of Dermatology, 1989, 125, 845.	1.4	0
485	Ataxia-telangiectasia. Journal of the American Academy of Dermatology, 1995, 32, 686.	1.2	0
486	Multiple Cutaneous Nodules in a Newborn. Pediatric Dermatology, 1995, 12, 59-62.	0.9	0

#	Article	IF	Citations
487	Collagen vascular diseases in children. Current Problems in Dermatology, 2000, 12, 177-182.	0.0	0
488	In This Issue: Genotype-Phenotype Correlations: Lessons Learned from â€˜Milderâ€™ Genodermatoses. Journal of Investigative Dermatology, 2003, 120, vi-vii.	0.7	0
489	Jorizzo JL, Crounse RG, Wheeler CE, Jr. Lamellar ichthyosis, dwarfism, mental retardation, and hair shaft abnormalities. J Am Acad Dermatol 1980;2:309-17.. Journal of the American Academy of Dermatology, 2005, 52, 630.	1.2	0
490	Prescribing Patterns by Dermatologists and Primary Care Providers for Pediatric Psoriasis. Archives of Dermatology, 2012, 148, 71.	1.4	0
491	Histological and Immunohistochemical Features of the Skin Lesions in CANDLE Syndrome. Pediatric Rheumatology, 2015, 13, .	2.1	0
492	Physician-Industry Collaboration: Organizational Considerations for the Future of Innovation and Growth in Dermatology. International Journal of Women's Dermatology, 2016, 2, 60-61.	2.0	0
493	Novel large animal model of xanthoma formation. Journal of Dermatological Science, 2016, 81, 203-205.	1.9	0
494	Reply to: â€œPrognosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysisâ€• Journal of the American Academy of Dermatology, 2017, 77, e119.	1.2	0
495	Biological Agents in Pediatric Dermatology. , 2018, , 267-271.		0
496	Alteraciones de la cornificaciÃ³n (ictiosis). , 2009, , 285-310.		0
497	Immunodeficiency Disorders. , 2010, , 575-588.		0
498	Hereditary Disorders of the Dermis. , 2011, , 115-129.		0
499	Current and Novel Approaches for Genetic Skin Disorders. , 2014, , 189-202.		0
500	Mosaicism and Epidermal Nevi. , 1998, , 713-717.		0
501	Biologics in Pediatric Psoriasis and Atopic Dermatitis: Revolutionizing the Treatment Landscape. , 2020, 106, 224-226;E1;E2.		0
502	Disorders of Pigmentation. , 2016, , 245-278.e8.		0
503	Collagen Vascular Disorders. , 2016, , 509-539.e8.		0
504	Cutaneous Tumors and Tumor Syndromes. , 2016, , 193-229.e6.		0

#	Article	IF	Citations
505	Disorders of the Sebaceous and Sweat Glands. , 2016, , 175-192.e3.		0